Prevalence of Juvenile-Onset and Pediatric Huntington’s Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study
Journal of Huntington's Disease · 2024
DOI: 10.3233/jhd-240034 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Huntington's Disease, 2024. Verfasst von Hannah S Bakels und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Huntington Disease, Age of Onset. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Juvenile-onset Huntington’s disease (JHD) represents 1–5% of Huntington’s disease (HD) patients, with onset before the age of 21. Pediatric HD (PHD) relates to a proportion of JHD patients that is still under 18 years of age. So far, both populations have been excluded from interventional trials.
Objective
Describe the prevalence and incidence of JHD and PHD in the Netherlands and explore their ability to participate in interventional trials.
Methods
The prevalence and incidence of PHD and JHD patients in the Netherlands were analyzed. In addition, we explored proportions of JHD patients diagnosed at pediatric versus adult age, their diagnostic delay, and functional and modelled (CAP100) disease stage in JHD and adult-onset HD patients at diagnosis.
Results
The prevalence of JHD and PHD relative to the total manifest HD population in January 2024 was between 0.84–1.25% and 0.09–0.14% respectively. The mean incidence of JHD patients being diagnosed was between 0.85–1.28 per 1000 patient years and of PHD 0.14 per 1.000.000 under-aged person years. 55% of JHD cases received a clinical diagnosis on adult age. At diagnosis, the majority of JHD patients was functionally compromised and adolescent-onset JHD patients were significantly less independent compared to adult-onset HD patients.
Conclusions
In the Netherlands, the epidemiology of JHD and PHD is lower than previously suggested. More than half of JHD cases are not eligible for trials in the PHD population. Furthermore, higher functional dependency in JHD patients influences their ability to participate in trials. Lastly, certain UHDRS functional assessments and the CAP100 score do not seem appropriate for this particular group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
Zitieren
APA
Bakels, H. S., Feleus, S., Rodríguez-Girondo, M., Losekoot, M., Bijlsma, E. K., Roos, R. A. C., & de Bot, S. T. (2024). Prevalence of Juvenile-Onset and Pediatric Huntington’s Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study. Journal of Huntington's Disease. https://doi.org/10.3233/jhd-240034
Vancouver
Bakels HS, Feleus S, Rodríguez-Girondo M, Losekoot M, Bijlsma EK, Roos RAC, et al. Prevalence of Juvenile-Onset and Pediatric Huntington’s Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study. Journal of Huntington's Disease. 2024. doi:10.3233/jhd-240034
BibTeX
@article{Bakels2024,
author = {Bakels, Hannah S and Feleus, Stephanie and Rodríguez-Girondo, Mar and Losekoot, Monique and Bijlsma, Emilia K and Roos, Raymund A C and de Bot, Susanne T},
title = {Prevalence of Juvenile-Onset and Pediatric Huntington’s Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study},
journal = {Journal of Huntington's Disease},
year = {2024},
doi = {10.3233/jhd-240034}
}
EUVIMED